Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients
Pancreatic cancer is a lethal disease with increasing incidence. Most patients present with advanced disease, for which palliative systemic chemotherapy is the only therapeutic option. Despite improved median survival rates with FOLFIRINOX or gemcitabine chemotherapy compared to the best supportive...
Main Authors: | Fleur van der Sijde, Eveline E. Vietsch, Dana A. M. Mustafa, Marc G. Besselink, Bas Groot Koerkamp, Casper H. J. van Eijck |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-01-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/11/1/93 |
Similar Items
-
Neoadjuvant Treatment Strategies in Resectable Pancreatic Cancer
by: Aurélien Lambert, et al.
Published: (2021-09-01) -
Chemoresistance in Pancreatic Cancer
by: Siyuan Zeng, et al.
Published: (2019-09-01) -
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
by: Lu Zou, et al.
Published: (2021-07-01) -
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
by: Sara Pusceddu, et al.
Published: (2019-04-01) -
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial
by: Q. P. Janssen, et al.
Published: (2021-03-01)